Today’s clinical labs are under mounting pressure to interpret next-generation sequencing (NGS) tests faster and with greater precision than ever before. That’s why we created QCI Interpret One.
With QCI Interpret One, lab directors can prepare, prioritize and report on clinically relevant variants associated with solid tumors and hematological malignancies without the time-consuming step of researching and writing variant- and disease-specific evidence summaries. Users get access to an “expert second opinion” for variant classification, and they can deliver professional reports directly to physicians and oncologists to better inform clinical decision making.
Join us on Thursday, June 11 at 11 a.m. EST for a live webinar on QCI Interpret One. Our experts will provide a demonstration of the clinical decision support software, as well as illustrate how the curation and interpretation services work, showing you first hand how QCI Interpret One can help your lab streamline, accelerate, and scale your clinical oncology NGS test interpretation workflow.
Immediately access over 170,000 decision-ready oncologist-reviewed variant interpretative comments, plus expertly curated professional guidelines, FDA therapies, clinical trials, and published literature, for confident decision-making.
Speed up variant interpretation with dynamically computed disease-specific variant classifications, immediate access to interpretive comments, and automatable workflows to help you scale for higher test volumes.
Generate customizable and standardized clinical reports with variant- and disease-specific information, including molecular function, and diagnostic, prognostic, and therapeutic relevance, available treatments, and open clinical trials.
The content core of QCI Interpret One, the QIAGEN Clinical Knowledge Base transforms unstructured data into actionable insight. By aggregating, manually curating, and modeling scientific literature and professional guidelines with semantic consistency, the QIAGEN Clinical Knowledge Base captures biological, phenotypic, therapeutic, and outcomes information that enables QCI Interpret One to compute variant- and disease-specific classifications for every alteration in every disease for every patient case.
QCI Interpret One enables clinical labs to speed up variant interpretation through automatable workflows and integrated curation and interpretation services.
QCI Interpret One gives you:
Decision-ready interpretations at your fingertips
Configurable and automatable workflows
On-demand clinical curation and interpretation services
Instantly prioritize clinically relevant variants
Dynamically compute disease-specific variant classifications and drug and trial selection
Generate customizable and standardized clinical reports
Access to variant- and disease-specific content
Expert decision-ready interpretations with oncologist-reviewed clinical evidence
The content, transparency, and delivery of clinical oncology NGS test reports are critical for timely and effective patient care. QCI Interpret One supports customizable and standardized reporting to ensure adherence with industry guidelines, while also making reports easy to understand and act upon by oncologists and clinicians.
QCI Interpret One is designed to augment in-house expertise. By providing you with all of the content necessary to generate a comprehensive, patient-specific report, yet giving you full control over final classifications, comments, and recommendations, the software and service enhance decision-making in the clinical workflow.
The best way to discover the benefits of QCI Interpret One is to request a free, no-obligation consultation tailored to your lab’s needs.
Clinical decision support software enabling faster test turnaround times and higher confidence reporting for any indication on your sequencing platform
Reimagine your clinical genomic interpretation with same day, expert variant classification services tailored to your oncology panel
Leverage the benefits of automation and expert support to improve test turnaround times and clinical reporting capabilities